Skip to Content
Merck
All Photos(1)

Documents

Safety Information

Q0632

Sigma-Aldrich

Quinapril hydrochloride

≥98% (HPLC), solid

Synonym(s):

(3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H30N2O5 · HCl
CAS Number:
82586-55-8
Molecular Weight:
474.98
MDL number:
MFCD00889215
UNSPSC Code:
41116107
PubChem Substance ID:
329823858
NACRES:
NA.77

Assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: >10 mg/mL

storage temp.

2-8°C

SMILES string

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(O)=O

InChI

1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1

InChI key

IBBLRJGOOANPTQ-JKVLGAQCSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Application

Quinapril hydrochloride has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on renal tubular epithelial cell proliferation in human renal tubular epithelial cells. It has also been used as an ACE inhibitor to evaluate its effects on the expression of angiotensin II (AII) in patient-derived Atheroma samples.

Biochem/physiol Actions

Quinapril has been studied to exhibit therapeutic effects against hypertension and congestive heart failure.
Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H361d,H372

Hazard Classifications

Repr. 2 - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

Q0632-VAR:
Q0632-BULK:
Q0632-500MG:
Q0632-250MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A M D Watson et al.
Diabetologia, 53(1), 192-203 (2009-10-29)
There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and
B Daan Westenbrink et al.
Heart (British Cardiac Society), 97(19), 1590-1596 (2011-07-16)
To investigate the association between sustained postoperative anaemia and outcome after coronary artery bypass graft (CABG) surgery. Retrospective analysis of the IMAGINE trial, which tested the effect of the ACE inhibitor quinapril on cardiovascular events after CABG. Thoracic surgery clinic/outpatient
G L Plosker et al.
Drugs, 48(2), 227-252 (1994-08-01)
Following systemic absorption, quinapril is converted by de-esterification to quinaprilat (the active diacid metabolite), an inhibitor of angiotensin converting enzyme (ACE). Pharmacodynamic studies in animals indicate inhibition of ACE both in plasma and at tissue sites, such as the arterial
Syed T Rahman et al.
Journal of cardiovascular pharmacology and therapeutics, 17(2), 139-145 (2011-07-14)
We sought to determine whether a combination of angiotensin-converting enzyme inhibitors (ACEIs) and the nutraceutical α-lipoic acid (ALA) regulates blood pressure, endothelial function, and proteinuria in diabetic patients with Stage I hypertension. A total of 40 diabetic patients with Stage
Christine R Culy et al.
Drugs, 62(2), 339-385 (2002-01-31)
Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril produces favourable haemodynamic changes, and improves ventricular and endothelial function in patients with various cardiovascular disorders; these effects are mediated
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service